| Medical treatment for congenital hereditary endothelial dystrophy |
Ongoing |
Nepafenac |
2 |
22071-CT |
King Khaled Eye Specialist Hospital (Riyadh) |
| Randomized, Open-Label, Clinical Trial for Evaluating the Prophylactic Use of Paracetamol for Fasting-induced Headache During the First Week of Ramadan |
Completed |
Paracetamol |
3 |
E-22-7145 |
King Khalid University Hospital (Riyadh) |
| Efficacy and safety of cinacalcet in children with secondary hyperparathyroidism due to Vitamin D resistant ricket, two arms, randomized clinical trial (Phase III). |
Ongoing |
MIMPARA 30MG F.C. TABLETS |
3 |
2.1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Comparison of IV ketamine with Standard Analgesia for treatment of vaso occlusive crisis in sickle cell disease." |
Ongoing |
ESKETAMINE HCL |
3 |
2211021 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A randomized double-blind placebo-controlled parallel group study assessing the efficacy and safety of dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS) |
Ongoing |
Dupilumab |
3 |
EFC16724 |
King Khalid University Hospital (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma. |
Ongoing |
PHE885 (CAR-T Cell) |
2 |
CPHE885B12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Stress Hydrocortisone in Pediatric Septic Shock (The SHIPSS trial) |
Ongoing |
Hydrocortisone |
4 |
SCT22R/009 |
King Abdulaziz Medical City NG (Riyadh) |
| iOUTRUN: Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients |
Ongoing |
Benralizumab |
4 |
D3250R0011 |
King Fahad Medical City (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah),International Medical Center (Jeddah) |
| "Nintedanib in patients with bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation – a multicentre phase II trial" |
Ongoing |
NINTEDANIB |
2 |
Amendment 3 F02 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An open-label, controlled, multi-site, Phase 2 clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle disorders (UCD) using a 15N ammonium chloride tracer compared to newborns and infants without UCD |
Rejected |
15NH4Cl tracer assay |
2 |
HLSC-UCD-01 |
King Abdulaziz Medical City NG (Riyadh) |
